PaxMedica announces that the Annals of General Psychiatry has accepted the manuscript titled “Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder” for publication. “The acceptance of this manuscript represents a significant milestone in PaxMedica’s continued dedication to pioneering innovative treatments for Autism Spectrum Disorder. We are honored to contribute to the field of psychiatry with this significant research, underscoring our commitment to advancing the understanding and treatment of ASD,” commented Dr. David Hough, Chief Medical Officer at PaxMedica.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PXMD:
- PaxMedica’s Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for Publication
- PaxMedica completes Type-B meeting with FDA for PAX-101 trial data
Questions or Comments about the article? Write to editor@tipranks.com